TITLE

HEMISPHERX'S CFS CLINICAL PROGRAMS REVIEWED IN EUROPE

PUB. DATE
February 2008
SOURCE
Worldwide Biotech;Feb2008, Vol. 20 Issue 2, p2
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports that the National Horizon Scanning Centre of the Department of Public Health and Epidemiology at the University of Birmingham in Great Britain has published a comprehensive "Report on CFS." The report focuses on the growing problems in Great Britain associated with Chronic Fatigue Syndrome (CFS), with specific attention given to Poly I: Poly C12U, an experimental drug developed by Hemispherx Biopharma Inc. as a potential aid in fighting the disease.
ACCESSION #
28720276

 

Related Articles

  • Clinic Roundup.  // BioWorld Today;3/20/2012, Vol. 23 Issue 44, p8 

    The article reports that Hemispherx Biopharma Inc. published the results of a Phase III trial of Ampligen in chronic fatigue in "PLoS ONE."

  • After Stock Bump, Hemispherx Bringing in $18.3M Publicly. Boggs, Jennifer // BioWorld Today;5/12/2009, Vol. 20 Issue 90, p3 

    The article reports on the decision of Hemispherx Biopharma Inc. to raise $18.3 million in public equity offerings in May 2009. The company agreed to sell common shares priced at $1.10 each to bring in $15 million, along with Series A warrants to purchase 6,136,364 shares of common stock. The...

  • In defense of Hemispherx. Nuccio, Sal // Equities;Jan/Feb99, Vol. 47 Issue 1, p27 

    Focuses on Pennsylvania-based pharmaceutical firm Hemispherx Biopharma Inc. Third-stage clinical testing for drug called Ampligen for the treatment of chronic fatigue syndrome; Sales expectations and earnings of the drug once approved by the United States Food and Drug Administration; Stock...

  • Hemispherx Files Ampligen NDA.  // Bioworld Week;10/15/2007, Vol. 15 Issue 42, p5 

    The article reports that Philadelphia-based Hemispherx Biopharma Inc. filed to the Food and Drug Authority (FDA) a new drug application for Ampligen in the treatment of chronic fatigue syndrome (CFS). According to Hemispherx, it included a massive regulatory package data, that goes back over a...

  • Ampligen & Chronic Fatigue. Klotter, Jule // Townsend Letter for Doctors & Patients;Aug/Sep2005, Issue 265/266, p24 

    Explains that Hemispherx Biopharma, Inc. has completed a Phase III Chronic Fatigue Syndrome (CFS) trial of Ampligen, a double-stranded RNAdrug. Modulation of the immune system; Antiviral agent; Randomized, double-blind, placebo-controlled, crossover study of 234 subjects; Treadmill exercise...

  • FDA to review Hemispherx's Ampligen NDA.  // PharmaWatch: Biotechnology;Aug2008, Vol. 7 Issue 8, p8 

    The article reports on the consideration for review of Hemispherx Biopharma Inc.'s new drug application (NDA) for Ampligen in the U.S. The company submitted its NDA for the experimental therapeutic to the Food and Drug Administration in October 2007. It states that Ampligen, an experimental...

  • Partner, NIH: Other Chances For Ampligen CFS Campaign? Osborne, Randy // BioWorld Today;2/11/2013, Vol. 24 Issue 28, p1 

    The article reports that the change on the use of a trial placebo for chronic fatigue syndrome (CFS) may hinder the regulatory efforts of Hemispherx Bioscience Inc. with Toll-like receptor 3 modulator Ampligen (rintatolimod). President Kimberly McCleary says that the situation cries out for the...

  • Hemispherx Down on Ampligen FDA Rejection, but not yet Out. Morrison, Trista // BioWorld Today;12/3/2009, Vol. 20 Issue 232, p1 

    The article reports that stock price of Hemispherx Biopharma Inc. fell by 41 percent following a letter from the U.S. Food and Drug Administration (FDA) regarding the Ampligen drug of the company. The Toll-like receptor 3 modulator has been evaluated for various diseases, including chronic...

  • FDA Workshop Examines CFS; Hope for Hemispherx, Patients? Osborne, Randy // BioWorld Today;3/ 7/2013, Vol. 24 Issue 44, p1 

    The article reports on the move of the Food and Drug Administration (FDA) to repurpose drug development in the U.S. It notes the agency's upcoming workshop to be held at the Marriott Hotel in Bethesda, Maryland from April 25-26, 2013, which will be focused on labeling drugs for chronic fatigue...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics